HIA, CBD maker file another legal action against DEA over hemp extracts

Briefs, CBD Products & CBD Business News, Drug Enforcement Administration, Hemp Cultivation, Processing & Extraction News, Hemp Industries Association, Hemp Industry News for Hemp & CBD Retailers, Hemp Legalization & Regulatory News for Hemp Businesses, Infused Products & Extraction, RE Botanicals, Regulatory, South Carolina Hemp Business & Legal News

The Hemp Industries Association and a South Carolina CBD manufacturer are asking a second federal court to prevent the U.S. Drug Enforcement Administration from criminalizing hemp extracts.

At issue is whether the DEA is simply updating its policies to comply with the 2018 Farm Bill, which removed low-THC cannabis from the Controlled Substances Act, or whether the DEA is making an illegal power grab by saying that hemp extracts are Schedule 1 controlled substances during a portion of the extraction process when the plant’s THC levels spike above what’s allowed.

The lawsuit filed Monday in D.C. District Court is the second legal action HIA and RE Botanicals have filed over the matter. Last month, HIA and RE Botanicals challenged the rule the DEA published in August on procedural grounds.

The latest lawsuit asks the court for an order blocking the DEA from enforcing its policy and prevent the agency from issuing any rules over hemp production.

Some CBD makers have said they’ll go out of business if the rule isn’t changed. The DEA is taking public comments on it through late October, and HIA and other hemp and marijuana associations have urged members to write letters of opposition before it takes effect.

The DEA rule isn’t final; the agency is taking public comments on it through next week.

Articles You May Like

Weed legalization: NJ voters mull controversial ballot question
Douglas R Smith – Toward Precision Medicine for Cannabidiol Treatment in Epilepsy…
What to Know Before Starting an Indoor Hemp Grow
Indiana wins USDA approval, while Tennessee bows out for another year
In Italy, a change on CBD medicine classification stokes confusion in hemp industry

Leave a Reply

Your email address will not be published. Required fields are marked *